DNMT1 Inhibitor Toxicity Reduction via Antioxidant Mediation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases like cancer often involve toxic drugs that can have adverse effects, and there is a need for methods to attenuate the activity of DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitors to reduce their toxicity while maintaining therapeutic efficacy.
Innovation Solution
Administering a composition comprising a DNMT1 inhibitor and an antioxidant, such as thiol-based antioxidants like N-acetylcysteine or glutathione, to animals undergoing cancer treatment to attenuate the activity of DNMT1 inhibitors, thereby reducing toxicity and maintaining antiproliferative effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNMT1 inhibitors are administered to treat cancer, then antiproliferative and cytotoxic effects are achieved, but toxic side effects increase
Solution Approach 1:
The patent introduces antioxidants as intermediary substances that mediate between the DNMT1 inhibitor and the cellular environment. These antioxidants specifically protect normal cells from the toxic effects of DNMT1 inhibitors while allowing the drugs to maintain their therapeutic efficacy against cancer cells, thus resolving the contradiction between effectiveness and toxicity
Solution Approach 2:
The patent applies the principle of local quality by creating different chemical environments in different cellular contexts. Antioxidants are administered to create a reducing environment that selectively neutralizes the toxic effects in normal cells, while cancer cells remain susceptible to the antiproliferative effects of DNMT1 inhibitors due to their altered redox state and higher oxidative stress
2Productivity
If the dose of DNMT1 inhibitor is increased to enhance therapeutic effect, then antiproliferative activity increases, but toxicity increases
Solution Approach 1:
Antioxidants serve as protective intermediaries that enable the administration of higher doses of DNMT1 inhibitors by buffering the toxic effects. This allows the system to achieve greater antiproliferative activity while the antioxidants simultaneously mitigate the proportional increase in toxicity that would otherwise occur
Solution Approach 2:
The patent implements beforehand cushioning by pre-administering or co-administering antioxidants before or during DNMT1 inhibitor treatment. This creates a protective buffer in advance that cushions the system against the toxic effects of high-dose DNMT1 inhibitors, allowing higher doses to be used safely
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively attenuates the activity of DNMT1 inhibitors, reducing their toxic side effects while preserving their ability to induce antiproliferative and cytotoxic effects in cancer cells, thereby providing a therapeutic benefit with reduced adverse reactions.
Implementation Method 1
administering a composition comprising a DNMT1 inhibitor and an antioxidant to attenuate the activity of the DNMT1 inhibitor
Data Source
AI summary
Some aspects of the invention include attenuating DNMT1 inhibitor activity in an animal comprising administering an antioxidant. Other aspects of the invention include methods comprising administering a composition comprising a DNMT1 inhibitor and an antioxidant. In some instances in the methods, the animal is undergoing a treatment for cancer. Additional aspects of the invention include compositions comprising a DNMT1 inhibitor and an antioxidant.